EMA — authorised 12 December 2014
- Marketing authorisation holder: Clinuvel UK Limited
- Status: approved
🇪🇺 Scenesse in European Union
EMA authorised Scenesse on 12 December 2014
Marketing authorisations
EMA — authorised 22 December 2014
- Application: EMEA/H/C/002548
- Marketing authorisation holder: Clinuvel Europe Limited
- Local brand name: Scenesse
- Indication: Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
- Pathway: exceptional circumstances
- Status: approved
Scenesse in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Rare Disease approved in European Union
Frequently asked questions
Is Scenesse approved in European Union?
Yes. EMA authorised it on 12 December 2014; EMA authorised it on 22 December 2014.
Who is the marketing authorisation holder for Scenesse in European Union?
Clinuvel UK Limited holds the EU marketing authorisation.